Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

Kyle M. Rose, Heather L. Huelster, Joshua J. Meeks, Bishoy M. Faltas, Guru P. Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit K. Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang, Roger Li*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.

Original languageEnglish (US)
JournalNature Reviews Urology
StateAccepted/In press - 2023

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease'. Together they form a unique fingerprint.

Cite this